Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Journal:

The New England Journal of Medicine

Published:

2025-10-20

DOI:

10.1056/nejmoa2511648

Affiliations:

24

Authors:

31

Go to article

Institutions	Authors	Share
RemeGen, Ltd., China	3.000000	0.10
Peking University First Hospital, PKUHSC, China	2.000000	0.06
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	2.000000	0.06
Hunan Cancer Hospital, China	2.000000	0.06
The First Affiliated Hospital, Zhejiang University School of Medicine, China	2.000000	0.06
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	2.000000	0.06
Henan Cancer Hospital, ZZU, China	1.000000	0.03
The First Affiliated Hospital of Chongqing Medical University, China	1.000000	0.03
The Affiliated Hospital of Qingdao University, China	1.000000	0.03
Affiliated Hospital, Guizhou Medical University, China	1.000000	0.03
Liaoning Cancer Hospital and Institute, China	1.000000	0.03
Hospital and Cancer Center, CQU, China	1.000000	0.03
Second Xiangya Hospital, CSU, China	1.000000	0.03
Sichuan Cancer Hospital, China	1.000000	0.03
Tumor Hospital of Guangxi Medical University, China	1.000000	0.03
Zhejiang Provincial People's Hospital, China	1.000000	0.03
Sun Yat-sen Memorial Hospital, SYSU, China	1.000000	0.03
Cancer Hospital of Yunnan Province, China	1.000000	0.03
Cancer Institute and Hospital, CAMS & PUMC, China	1.000000	0.03
Shandong Cancer Hospital, China	1.000000	0.03
The First Affiliated Hospital of Fujian Medical University, China	1.000000	0.03
The First Hospital of Jilin University, China	1.000000	0.03
The First Affiliated Hospital of Wenzhou Medical University, China	1.000000	0.03
Tongji University, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?